June 2, 2020
Authored and Edited by K. Victoria Barker, Ph.D.; Maeve O'Flynn
Last week, we hosted a webinar discussing strategies for drafting chemical and life science patent applications to aid prosecution and enforcement in the US and Europe. A link to the webinar can be found here.
We’ve summarized below our “top tips” for minimizing future added matter issues at the EPO when drafting, while avoiding patent profanity at the USPTO:
1. At the EPO, amendments that create “new” combinations are a particular problem. Consider filing with multiply dependent claims or include a “numbered embodiments” section to provide basis for combinations in the future.
2. At the EPO, the term “comprising” may not provide basis for “consisting of”. Consider including embodiments with both terms e.g. “a pharmaceutical formulation comprising X, Y, Z” and “a pharmaceutical formulation consisting of X, Y, Z”.
3. It is difficult to rely on the Examples or Figures as basis for amendments at the EPO, particularly if you wish to extract one feature in isolation. Consider adding falls backs to the key features of the Examples and Figures in the description.
4. At the EPO, basis for amendments must derive from the application as originally filed. This excludes the abstract and the priority document. Information that has been “incorporated by reference” can only be relied upon as basis for amendments in very limited circumstances.
5. Use consistent terminology when drafting. For example, the terms “pharmaceutical formulation” and “pharmaceutical composition” could easily be used interchangeably when drafting, but an EPO Examiner may not allow embodiments relating to the formulation to be combined with embodiments relating to the composition as these are (arguably) different things.
For further advice, please contact your European representative.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.